Physician profile
Steven Crum
NPI 1275599755
$16,764.83
in general payments reported to CMS, 2019-2025
46 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,211 · 2020: $2,419 · 2021: $2,804 · 2022: $2,225 · 2023: $1,952 · 2024: $2,860 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,094 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,093.90 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,387.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,283.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,674.60 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,350.99 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $1,340.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,223.21 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $902.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $757.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $616.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $601.60 | 2019-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $355.15 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $354.79 | 2019-2025 | Lagevrio, Dificid |
| Amgen INC. | $342.24 | 2020-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $312.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $274.03 | 2019-2024 | Trintellix |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Crum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.